← Back to Screener
Tandem Diabetes Care, Inc. (TNDM)
Price$21.24
Favorite Metrics
Price vs S&P 500 (26W)38.47%
Price vs S&P 500 (4W)-26.46%
Market Capitalization$1.47B
All Metrics
Book Value / Share (Quarterly)$2.27
P/TBV (Annual)10.39x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)8.19%
Cash Flow / Share (Quarterly)$-0.43
Price vs S&P 500 (YTD)-10.37%
Gross Margin (TTM)53.81%
Net Profit Margin (TTM)-20.17%
EPS (TTM)$-3.07
10-Day Avg Trading Volume1.53M
EPS Excl Extra (TTM)$-3.07
Revenue Growth (5Y)15.26%
EPS (Annual)$-3.04
ROI (Annual)-43.55%
Gross Margin (Annual)53.81%
Net Profit Margin (5Y Avg)-13.95%
Cash / Share (Quarterly)$4.29
Revenue Growth QoQ (YoY)2.74%
ROA (Last FY)-23.23%
Revenue Growth TTM (YoY)7.93%
EBITD / Share (TTM)$-2.52
ROE (5Y Avg)-51.46%
Operating Margin (TTM)-18.45%
Cash Flow / Share (Annual)$-0.43
P/B Ratio9.50x
P/B Ratio (Quarterly)9.60x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.67x
Net Interest Coverage (TTM)-14.39x
ROA (TTM)-23.04%
EV / EBITDA (TTM)246.06x
EPS Incl Extra (Annual)$-3.04
Current Ratio (Annual)2.55x
Quick Ratio (Quarterly)1.89x
3-Month Avg Trading Volume1.85M
52-Week Price Return19.41%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.10
P/S Ratio (Annual)1.45x
Asset Turnover (Annual)1.15x
52-Week High$29.65
Operating Margin (5Y Avg)-13.73%
EPS Excl Extra (Annual)$-3.04
CapEx CAGR (5Y)-9.19%
Tangible BV CAGR (5Y)-16.69%
26-Week Price Return47.21%
Quick Ratio (Annual)1.89x
13-Week Price Return-1.25%
Total Debt / Equity (Annual)2.03x
Current Ratio (Quarterly)2.55x
Enterprise Value$1,697.828
Revenue / Share Growth (5Y)13.02%
Asset Turnover (TTM)1.14x
Book Value / Share Growth (5Y)-17.32%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)3.37x
Pretax Margin (Annual)-19.74%
Cash / Share (Annual)$4.29
3-Month Return Std Dev89.81%
Gross Margin (5Y Avg)52.03%
Net Income / Employee (TTM)$-0
EBITDA Interim CAGR (5Y)-10.36%
ROE (Last FY)-131.93%
Net Interest Coverage (Annual)-14.39x
EPS Basic Excl Extra (Annual)$-3.04
P/FCF (TTM)202.52x
Receivables Turnover (TTM)7.25x
Total Debt / Equity (Quarterly)2.03x
EPS Incl Extra (TTM)$-3.07
Receivables Turnover (Annual)7.25x
ROI (TTM)-43.68%
P/S Ratio (TTM)1.45x
Pretax Margin (5Y Avg)-13.66%
Revenue / Share (Annual)$15.08
Tangible BV / Share (Annual)$2.10
Price vs S&P 500 (52W)-15.69%
Year-to-Date Return-6.23%
5-Day Price Return2.54%
EPS Normalized (Annual)$-3.04
ROA (5Y Avg)-12.76%
Net Profit Margin (Annual)-20.17%
Month-to-Date Return7.51%
Cash Flow / Share (TTM)$-2.98
EBITD / Share (Annual)$-2.52
Operating Margin (Annual)-18.45%
LT Debt / Equity (Annual)2.03x
ROI (5Y Avg)-21.38%
LT Debt / Equity (Quarterly)2.03x
EPS Basic Excl Extra (TTM)$-3.07
P/TBV (Quarterly)10.39x
P/B Ratio (Annual)9.60x
Inventory Turnover (TTM)3.37x
Pretax Margin (TTM)-19.74%
Book Value / Share (Annual)$2.27
Price vs S&P 500 (13W)-4.11%
Beta1.69x
P/FCF (Annual)196.47x
Revenue / Share (TTM)$14.92
ROE (TTM)-141.98%
52-Week Low$9.98
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.63
3.63
3.70
3.79
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
TNDMTandem Diabetes Care, Inc. | 1.45x | 15.26% | 53.81% | -18.45% | $21.24 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Tandem Diabetes designs and manufactures insulin pumps and related disposables for diabetes management. Since entering the market in 2012, the company has built a portfolio including its flagship t:slim X2 device and recently launched Mobi pump, with tubeless options (Tobi and Sigi) in development. Pumps account for approximately half of revenue, with disposable infusion sets representing one-third of sales. The company derives roughly 75% of revenue from the US market, with the remainder from other developed nations.